SKYE - skyebioscience.com Trailing Twelve Months Revenue Growth

Brandmark of Skye Bioscience (SKYE)

The primary driver for Skye Bioscience, Inc. (SKYE) is the expansion of its portfolio of treatments for obesity and metabolic disorders. Year-over-year sales dynamics over the last 12 months (TTM) visualize this growth, where the value of 0.00 reflects this status. Supply reliability is ensured by strict government control of cannabinoids, while the implementation of laboratory robotics accelerates primary molecule screening, creating new business opportunities.

SKYE - Skye Bioscience Inc. Sales Growth YoY (TTM) over the range 11/23/2025 - 11/18/2026

Summary analytical data breakdowns for Skye Bioscience Inc. (SKYE)

- market value and analyst target forecast:
Analysis of all company metrics:SKYE Skye Bioscience
Signature product of Skye Bioscience

The development of innovative synthetic cannabinoids for the treatment of obesity and glaucoma defines the scaling potential of Skye Bioscience, Inc. (SKYE). By analyzing the TTM revenue growth rate, an investor assesses sales dynamics over the last twelve months relative to the previous year, which allows for the identification of the company's expansion sustainability and the timely determination of overpayment risks at the peak of the market cycle.